Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathy

Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathy

Following the previously published results of the clinical randomized ZeOxaNMulti trial, we evaluated the potential of the tested product PMA-ZEO (Multizeo Med) in the prevention of chemotherapy-induced side effects (especially peripheral neuropathy) within a 30-month follow-up analysis. The aim was...

Full description

Bibliographic Details
Main Authors: Maria Giuseppa Vitale, Anna Crispo, Dario Arundine, Riccardo Ronga, Carmela Barbato, Assunta Luongo, Francesco Habetswallner, Bernardo Maria De Martino, Angela Maione, Sandra Eisenwagen, Giovanna Vitale, Ferdinando Riccardi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Pharmacology
Subjects:
oxaliplatin
PMA-zeolite
chemotherapy-induced peripheral neuropathy
colorectal cancer
disease-free survival
progression-free survival
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.874028/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.874028/full

Similar Items